I. Estimate the maximum tolerated dose (MTD) of decitabine when used sequentially or concomitantly with filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride (G-CLAM) independently in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).